Vigonvita Life Sciences — Biomedical Watch V2

Traitements4programmes

Essais1liés

Publications0liées

SourceDBlocale

Traitements

4

Molécule	Indication / population	Phase	Objectif	Pays	Résultat
Simenafil Hydrochloride Tablets 10 mgThis study is a multicenter, randomized, double-Blind, placebo-controlled Phase 2 clinical study to evaluate the efficacy and safety of Simenafil Hydrochloride Tablets in the treatment of participants with Alzheimer's Disease	Alzheimer	Phase 2	À vérifier	China	À vérifier
Simenafil Hydrochloride Tablets 2.5 mgThis study is a multicenter, randomized, double-Blind, placebo-controlled Phase 2 clinical study to evaluate the efficacy and safety of Simenafil Hydrochloride Tablets in the treatment of participants with Alzheimer's Disease	Alzheimer	Phase 2	À vérifier	China	À vérifier
Simenafil Hydrochloride Tablets 5 mgThis study is a multicenter, randomized, double-Blind, placebo-controlled Phase 2 clinical study to evaluate the efficacy and safety of Simenafil Hydrochloride Tablets in the treatment of participants with Alzheimer's Disease	Alzheimer	Phase 2	À vérifier	China	À vérifier
Simenafil Hydrochloride Tablets 2.5 mgThis study is a multicenter, randomized, double-Blind, placebo-controlled Phase 2 clinical study to evaluate the efficacy and safety of Simenafil Hydrochloride Tablets in the treatment of participants with Alzheimer's Disease	Alzheimer	Phase 2	À vérifier	China	À vérifier

Essais cliniques

1

Molécule	Indication / population	Phase	NCT	Titre	Statut
Simenafil Hydrochloride Tablets 2.5 mg	Alzheimer	Phase 2	NCT07905352	A Phase 2 Clinical Study of Simenafil Hydrochloride Tablets in the Treatment of Alzheimer's Disease	NOT_YET_RECRUITING

Publications

0

Molécule	Indication / population	Titre	Journal	Date
Aucune publication.